Press Release

Follow this link:
Mendus to hold Business Update event on March 12

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.

More here:
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

BETHESDA, Md., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity and software services company focused on the federal government, announces that it has closed its previously announced $4 million financing with Live Oak Bank.

See the rest here:
Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank

CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene. If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Read the original post:
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO® (berotralstat) that showed patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor (C1-INH) level and function.

Originally posted here:
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat)...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe

Read the original here:
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI

Link:
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge® (omidubicel-onlv)

Go here to read the rest:
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

Continue reading here:
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

More here:
Ocuphire Pharma to Present in the BIO CEO & Investor Conference

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Follow this link:
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)

Visit link:
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.

Read more from the original source:
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual...

The rest is here:
Curia Appoints Steve Lavezoli as Vice President, Biologics

Originally posted here:
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG

See original here:
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today announced that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will present and host one-on-one meetings at the BIO CEO & Investor Conference being held in New York City, February 26-27, 2024. Details for the event are as follows:

See the original post:
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024

Company Announcement

Follow this link:
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Visit link:
Celularity Announces 1-for-10 Reverse Stock Split

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $12.2 billion[1]. Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

See the original post:
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free...